These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 33457265)
21. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer. Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396 [TBL] [Abstract][Full Text] [Related]
22. Bladder sparing surgery in high-grade bladder cancer. Yakovlev PG; Klyushin DA; Vereshchako RI Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149 [TBL] [Abstract][Full Text] [Related]
24. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971 [TBL] [Abstract][Full Text] [Related]
25. Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer. Ajib K; Tjong MC; Tan GH; Nason GJ; Berjaoui MB; Erlich A; Maganti M; Sridhar SS; Fleshner NE; Zlotta AR; Catton C; Berlin A; Chung P; Kulkarni GS Can Urol Assoc J; 2020 Dec; 14(12):404-410. PubMed ID: 32569566 [TBL] [Abstract][Full Text] [Related]
26. Transurethral resection of bladder tumor-based bladder preservation therapy for refractory high risk non-muscle invasive bladder cancer: Current landscape and future directions. Sun X; Dai T; Xu L Front Surg; 2023; 10():1143219. PubMed ID: 37123545 [TBL] [Abstract][Full Text] [Related]
27. Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients. Rehme C; Fritsch B; Thomas L; Istin S; Burchert C; Hummel B; Baleanu-Curaj B; Reis H; Szarvas T; Ruebben H; Hadaschik B; Niedworok C Int Urol Nephrol; 2022 Jan; 54(1):71-79. PubMed ID: 34817753 [TBL] [Abstract][Full Text] [Related]
28. Trimodal therapy versus radical cystectomy for cT2N0M0 urothelial muscle-invasive bladder cancer: Single-center experience. Fallatah M; Alkahtani AS; Alrumayyan M; Alotaibi MF; Alkhateeb S; Mokhtar AA; Altaweel W Urol Ann; 2023; 15(4):406-411. PubMed ID: 38074180 [TBL] [Abstract][Full Text] [Related]
29. [OUTCOME OF BLADDER PRESERVATION USING LOW DOSE CHEMORADIATION THERAPY IN PATIENTS WITH LOCALLY INVASIVE BLADDER CANCER]. Matsushita M; Kitakaze H; Okada K; Minato N; Mori N; Yoshioka T Nihon Hinyokika Gakkai Zasshi; 2018; 109(2):59-67. PubMed ID: 31006743 [TBL] [Abstract][Full Text] [Related]
30. Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis. Su X; Dong C; Liao W; Liu W World J Surg Oncol; 2023 Aug; 21(1):271. PubMed ID: 37641150 [TBL] [Abstract][Full Text] [Related]